Non-Glucocorticoid Immunosuppressive Therapy in Post-Glucocorticoid Persistent or Recurrent Primary Autoimmune Hypophysitis: A Systematic Review.
Clin Endocrinol (Oxf)Jul 14, 2026 (epub)
Clinical ResearchEndocrinology
Parag Agrawal, Chethan Yami Channaiah, Anurag Ranjan Lila et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the effectiveness and safety of non-glucocorticoid immunosuppressive therapy (NGIT) in 29 patients with persistent or recurrent primary autoimmune hypophysitis (PAH) following glucocorticoid treatment. The study found that approximately 91% of patients achieved clinical remission, with the highest radiological response observed in those treated with rituximab (100%).
Key findings
- 62.1% of patients had recurrent disease after initial glucocorticoid therapy.
- 91% of patients achieved clinical remission with NGIT.
- Radiological response was best with rituximab at 100%.
Why it matters
Understanding the effectiveness of NGIT in managing persistent or recurrent PAH is crucial for clinicians, as it provides alternative treatment options for patients who do not respond to glucocorticoids, potentially improving patient outcomes.